Protective effects of Herbal Compound (IM253) on the inflammatory responses and oxidative stress in a mouse model of multiple sclerosis


      Multiple sclerosis (MS) is a multifactorial chronic inflammatory demyelinating disease of the central nervous system with both immune and neurodegenerative components as the underlying causes. Cytokines are key components of the inflammatory processes and their crucial roles in the inflammatory aspect of MS are undeniable. Several studies have pointed to the apparent change in Cytokines in MS. The aim of this study was to investigate the effects of IM253 treatment on inflammation and antioxidant defense in the cerebral corpus callosum of the C57BL/6 mouse, an Experimental autoimmune encephalomyelitis (EAE) model and as a most commonly used experimental model of MS. During the course of study, clinical evaluation was performed and eventually histological and molecular analysis on brain samples was carried out. Gene expression analyses demonstrated that treatment with IM253 causes a significant reduction in the expression of pro-inflammatory cytokine coding genes including IL-6, TNF-α, IFN-γ, and IL-17 as well as a significant increase in the expression of anti-inflammatory and anti-oxidant enzyme coding genes including TGF-β, GPX-1, and Cat. Histological studies also show that treatment with IM253 can reduce demyelination and inflammation (p<0.001). In addition, the GPX-1 enzyme activity evaluation also demonstrated that total antioxidant capacity was significantly higher in IM253 treated mice (p<0.001). Overall, our results suggest that IM253 could ameliorate the severity of EAE, probably because of its anti-inflammatory and anti-oxidant properties, and support the preclinical effects of IM253 as a potential therapeutic intervention.


      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Multiple Sclerosis and Related Disorders
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Acs P.
        • et al.
        17β-estradiol and progesterone prevent cuprizone provoked demyelination of corpus callosum in male mice.
        Glia. 2009; 57: 807-814
        • Aggarwal B.B.
        • Harikumar K.B.
        Potential therapeutic effects of curcumin, the anti-inflammatory agent, against neurodegenerative, cardiovascular, pulmonary, metabolic, autoimmune and neoplastic diseases.
        Int. J. Biochem. Cell Biol. 2009; 41: 40-59
        • Aharoni R.
        • et al.
        Distinct pathological patterns in relapsing–remitting and chronic models of experimental autoimmune enchephalomyelitis and the neuroprotective effect of glatiramer acetate.
        J. Autoimmun. 2011; 37: 228-241
      1. Baghaei, A., et al., Efficacy of Setarud (IMOD®), a novel drug with potent anti-toxic stress potential in rat inflammatory bowel disease and comparison with dexamethasone and infliximab.2010.

        • Bazazzadegan N.
        • et al.
        Effects of Herbal Compound (IMOD) on Behavior and Expression of Alzheimer’s Disease Related Genes in Streptozotocin-Rat Model of Sporadic Alzheimer’s Disease.
        Adv. Pharm. Bull. 2017; 7: 491
        • Chabaud M.
        • et al.
        Human interleukin-17: AT cell–derived proinflammatory cytokine produced by the rheumatoid synovium.
        Arthritis & Rheumatism: Official Journal of the American College of Rheumatology. 1999; 42: 963-970
        • Daneshmand P.
        • et al.
        Neuroprotective effects of herbal extract (Rosa canina, Tanacetum vulgare and Urtica dioica) on rat model of sporadic Alzheimer’s disease.
        Avicenna J. Med. Biotechnol. 2016; 8: 120
        • Esmaeilzadeh E.
        • et al.
        Shikonin protects dopaminergic cell line PC12 against 6-hydroxydopamine-mediated neurotoxicity via both glutathione-dependent and independent pathways and by inhibiting apoptosis.
        Neurochem. Res. 2013; 38: 1590-1604
        • Esmaeilzadeh E.
        • et al.
        Curcumin ameliorates experimental autoimmune encephalomyelitis in a C57BL/6 mouse model.
        Drug Dev. Res. 2019; 80: 629-636
        • Ghanavati R.
        • Namjoyan F.
        • Zadeh H.R.
        A review of possible herbal treatment in multiple sclerosis in traditional persian medicine.
        Iran. J. Med. Sci. 2016; 41 (Suppl): S18
        • Gold R.
        • Hartung H.-P.
        • Toyka K.V.
        Animal models for autoimmune demyelinating disorders of the nervous system.
        Mol. Med. Today. 2000; 6: 88-91
        • Groom M.J.
        • et al.
        Assessing mood in patients with multiple sclerosis.
        Clin. Rehabil. 2003; 17: 847-857
        • Guy J.
        Optic nerve degeneration in experimental autoimmune encephalomyelitis.
        Ophthalmic Res. 2008; 40: 212-216
        • Haas J.
        • et al.
        Reduced suppressive effect of CD4+ CD25high regulatory T cells on the T cell immune response against myelin oligodendrocyte glycoprotein in patients with multiple sclerosis.
        Eur. J. Immunol. 2005; 35: 3343-3352
        • Horstmann L.
        • et al.
        Inflammatory demyelination induces glia alterations and ganglion cell loss in the retina of an experimental autoimmune encephalomyelitis model.
        J. Neuroinflammation. 2013; 10: 888
        • Iarlori C.
        • et al.
        Reduction of free radicals in multiple sclerosis: effect of glatiramer acetate (Copaxone®).
        Mult. Scler. J. 2008; 14: 739-748
        • Koch M.
        • et al.
        Oxidative stress in serum and peripheral blood leukocytes in patients with different disease courses of multiple sclerosis.
        J. Neurol. 2006; 253: 483-487
        • Komiyama Y.
        • et al.
        IL-17 plays an important role in the development of experimental autoimmune encephalomyelitis.
        J. Immunol. 2006; 177: 566-573
        • Kuhlmann C.R.
        • et al.
        Inhibition of the myosin light chain kinase prevents hypoxia-induced blood–brain barrier disruption.
        J. Neurochem. 2007; 102: 501-507
        • Lassmann H.
        • Van Horssen J.
        • Mahad D.
        Progressive multiple sclerosis: pathology and pathogenesis.
        Nat. Rev. Neurol. 2012; 8: 647
        • Lee D.-H.
        • Gold R.
        • Linker R.A.
        Mechanisms of oxidative damage in multiple sclerosis and neurodegenerative diseases: therapeutic modulation via fumaric acid esters.
        Int. J. Mol. Sci. 2012; 13: 11783-11803
        • Lock C.
        • et al.
        Gene-microarray analysis of multiple sclerosis lesions yields new targets validated in autoimmune encephalomyelitis.
        Nat. Med. 2002; 8: 500
        • Lubina-Dąbrowska N.
        • et al.
        Effects of IFN-β1a and IFN-β1b treatment on the expression of cytokines, inducible NOS (NOS type II), and myelin proteins in animal model of multiple sclerosis.
        Arch. Immunol. Ther. Exp. (Warsz.). 2017; 65: 325-338
        • Mahmoodpoor A.
        • et al.
        Examination of Setarud (IMOD™) in the management of patients with severe sepsis.
        Daru: journal of Faculty of Pharmacy, Tehran University of Medical Sciences. 2010; 18: 23
        • Mantel P.-Y.
        • Schmidt-Weber C.B.
        Transforming growth factor-beta: recent advances on its role in immune tolerance, in Suppression and Regulation of Immune Responses.
        Springer, 2010: 303-338
        • Mirshafiey A.
        • Mohsenzadegan M.
        TGF-β as a promising option in the treatment of multiple sclerosis.
        Neuropharmacology. 2009; 56: 929-936
        • Mohraz M.
        • et al.
        A clinical trial on the efficacy of IMOD in AIDS patients. 17. Daru, 2009
        • Molina-Holgado E.
        • et al.
        LPS/IFN-γ cytotoxicity in oligodendroglial cells: role of nitric oxide and protection by the anti-inflammatory cytokine IL-10.
        Eur. J. Neurosci. 2001; 13: 493-502
        • Oreja-Guevara C.
        • et al.
        TH1/TH2 Cytokine profile in relapsing-remitting multiple sclerosis patients treated with Glatiramer acetate or Natalizumab.
        BMC Neurology. 2012; 12: 95
        • Owens T.
        • Sriram S.
        The immunology of multiple sclerosis and its animal model, experimental allergic encephalomyelitis.
        Neurol. Clin. 1995; 13: 51-73
        • Özenci V.
        • et al.
        Multiple sclerosis is associated with an imbalance between tumour necrosis factor-alpha (TNF-α)-and IL-10-secreting blood cells that is corrected by interferon-beta (IFN-β) treatment.
        Clin. Exp. Immunol. 2000; 120: 147-153
        • Paydary K.
        • Emamzadeh-Fard S.
        • Reza Khorram Khorshid H.
        • Kamali K.
        • SeyedAlinaghi S.
        • Mohraz M.
        Safety and efficacy of Setarud (IMOD TM) among people living with HIV/AIDS: a review.
        Recent Pat. Antiinfect. Drug Discov. 2012; 7: 66-72
        • Petković F.
        • Castellano B.
        The role of interleukin-6 in central nervous system demyelination.
        Neural Regen. Res. 2016; 11: 1922
        • Popko B.
        • et al.
        The effects of interferon-γ on the central nervous system.
        Mol. Neurobiol. 1997; 14: 19-35
        • Qin X.
        • et al.
        Regulation of Th1 and Th17 cell differentiation and amelioration of experimental autoimmune encephalomyelitis by natural product compound berberine.
        J. Immunol. 2010; 0903853
        • Shin T.
        • Ahn M.
        • Matsumoto Y.
        Mechanism of experimental autoimmune encephalomyelitis in Lewis rats: recent insights from macrophages.
        Anat. Cell Biol. 2012; 45: 141-148
        • Soleimani M.
        • et al.
        Effects of Coenzyme Q10 on the ratio of TH1/TH2 in Experimental Autoimmune Encephalomyelitis Model of Multiple Sclerosis in C57BL/6.
        Iran. Biomed. J. 2014; 18: 203
        • Sosa R.A.
        • et al.
        IFN-γ ameliorates autoimmune encephalomyelitis by limiting myelin lipid peroxidation.
        Proc. Natl. Acad. Sci. 2015; 112: E5038-E5047
        • St Clair D.K.
        • Chow C.K.
        Glutathione peroxidase: activity and steady-state level of mRNA.
        Oril Press, Oxford, United Kingdom1996
        • Stoll G.
        • et al.
        Tumor necrosis factor-α in immune-mediated demyelination and Wallerian degeneration of the rat peripheral nervous system.
        J. Neuroimmunol. 1993; 45: 175-182
        • Wang K.
        • Song F.
        • Fernandez-Escobar A.
        • Luo G.
        • Wang J.H.
        • Sun Y.
        The properties of cytokines in multiple sclerosis: pros and cons.
        Am. J. Med. Sci. 2018; 356: 552-560
        • Wong C.
        • et al.
        Elevation of proinflammatory cytokine (IL-18, IL-17, IL-12) and Th2 cytokine (IL-4) concentrations in patients with systemic lupus erythematosus.
        Lupus. 2000; 9: 589-593